Apricus Biosciences Company Profile (NASDAQ:APRI)

About Apricus Biosciences (NASDAQ:APRI)

Apricus Biosciences logoApricus Biosciences, Inc. is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company's drug delivery technology is a permeation enhancer called NexACT. The Company has over two product candidates in Phase II development, fispemifene for the treatment of symptomatic male secondary hypogonadism and RayVa for the treatment of Raynaud's phenomenon, secondary to scleroderma. The Company has a commercial product, Vitaros for the treatment of erectile dysfunction (ED), which is in development in the United States, approved in Canada and marketed throughout Europe.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:APRI
  • CUSIP: N/A
  • Web: www.apricusbio.com
  • Market Cap: $23.27 million
  • Outstanding Shares: 12,783,000
Average Prices:
  • 50 Day Moving Avg: $1.78
  • 200 Day Moving Avg: $1.37
  • 52 Week Range: $0.86 - $4.07
  • Trailing P/E Ratio: 3.04
  • Foreward P/E Ratio: 1.22
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $5.76 million
  • Price / Sales: 4.04
  • Book Value: $0.51 per share
  • Price / Book: 3.57
  • EBITDA: ($10,050,000.00)
  • Return on Assets: -91.93%
  • Current Ratio: 4.70%
  • Quick Ratio: 4.70%
  • Average Volume: 379,060 shs.
  • Beta: 0.52
  • Short Ratio: 3.14

Frequently Asked Questions for Apricus Biosciences (NASDAQ:APRI)

What is Apricus Biosciences' stock symbol?

Apricus Biosciences trades on the NASDAQ under the ticker symbol "APRI."

How were Apricus Biosciences' earnings last quarter?

Apricus Biosciences, Inc (NASDAQ:APRI) released its quarterly earnings data on Wednesday, August, 2nd. The company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.01. View Apricus Biosciences' Earnings History.

When will Apricus Biosciences make its next earnings announcement?

Apricus Biosciences is scheduled to release their next quarterly earnings announcement on Monday, November, 6th 2017. View Earnings Estimates for Apricus Biosciences.

Where is Apricus Biosciences' stock going? Where will Apricus Biosciences' stock price be in 2017?

2 brokers have issued 12-month target prices for Apricus Biosciences' shares. Their forecasts range from $4.50 to $4.50. On average, they anticipate Apricus Biosciences' stock price to reach $4.50 in the next twelve months. View Analyst Ratings for Apricus Biosciences.

Who are some of Apricus Biosciences' key competitors?

Who are Apricus Biosciences' key executives?

Apricus Biosciences' management team includes the folowing people:

  • Kleanthis G. Xanthopoulos Ph.D., Chairman of the Board
  • Richard W. Pascoe, Chief Executive Officer, Principal Accounting Officer, Secretary, Director
  • Brian T. Dorsey, Senior Vice President, Chief Development Officer
  • Paul V. Maier, Independent Director
  • Rusty Ray, Independent Director
  • Sandford D. Smith, Independent Director
  • Wendell Wierenga Ph.D., Independent Director

How do I buy Apricus Biosciences stock?

Shares of Apricus Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Apricus Biosciences' stock price today?

One share of Apricus Biosciences stock can currently be purchased for approximately $1.82.

MarketBeat Community Rating for Apricus Biosciences (NASDAQ APRI)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  90 (Vote Outperform)
Underperform Votes:  77 (Vote Underperform)
Total Votes:  167
MarketBeat's community ratings are surveys of what our community members think about Apricus Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Apricus Biosciences (NASDAQ:APRI) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $4.50 (147.25% upside)
Consensus Price Target History for Apricus Biosciences (NASDAQ:APRI)
Price Target History for Apricus Biosciences (NASDAQ:APRI)
Analysts' Ratings History for Apricus Biosciences (NASDAQ:APRI)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/5/2017HC WainwrightReiterated RatingBuy$4.50MediumView Rating Details
4/26/2017Rodman & RenshawInitiated CoverageBuy -> BuyLowView Rating Details
3/15/2016Taglich BrothersLower Price TargetSpeculative Buy$4.25 -> $2.95N/AView Rating Details
3/11/2016Dawson JamesReiterated RatingBuyN/AView Rating Details
12/9/2015Sterne Agee CRTDowngradeBuy -> NeutralN/AView Rating Details
11/6/2015Roth CapitalDowngradeBuy -> Neutral$1.50N/AView Rating Details
(Data available from 10/22/2015 forward)


Earnings History for Apricus Biosciences (NASDAQ:APRI)
Earnings by Quarter for Apricus Biosciences (NASDAQ:APRI)
Earnings History by Quarter for Apricus Biosciences (NASDAQ APRI)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017($0.15)N/AView Earnings Details
8/2/2017Q2 2017($0.16)($0.15)ViewListenView Earnings Details
5/11/2017Q1 2017$1.25$1.04$12.00 millionViewN/AView Earnings Details
3/13/2017Q4 2016($0.15)($0.04)$3.44 million$0.40 millionViewN/AView Earnings Details
11/8/2016Q316($0.60)($0.19)$1.91 million$4.30 millionViewListenView Earnings Details
8/4/2016Q216($0.08)($0.05)$1.78 million$0.46 millionViewListenView Earnings Details
5/9/2016Q116($0.09)($0.09)$0.83 million$0.63 millionViewN/AView Earnings Details
3/9/2016Q415($0.11)($0.05)$1.81 million$2.60 millionViewListenView Earnings Details
11/5/2015Q315($0.11)($0.10)$1.42 million$1.30 millionViewListenView Earnings Details
8/5/2015Q2($0.13)($0.10)$0.70 million$0.46 millionViewListenView Earnings Details
5/11/2015Q1($0.10)($0.13)$0.95 million$0.48 millionViewListenView Earnings Details
3/16/2015Q4($0.12)($0.09)$0.67 million$1.91 millionViewListenView Earnings Details
11/10/2014Q314($0.09)($0.08)$1.23 million$1.90 millionViewN/AView Earnings Details
5/12/2014Q114($0.03)($0.09)$2.83 millionViewN/AView Earnings Details
3/17/2014Q212($0.06)($0.04)$2.00 million$0.36 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Apricus Biosciences (NASDAQ:APRI)
2017 EPS Consensus Estimate: ($0.06)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.04)($0.04)($0.04)
Q2 20171($0.01)($0.01)($0.01)
Q3 20171($0.02)($0.02)($0.02)
Q4 20171$0.01$0.01$0.01
(Data provided by Zacks Investment Research)


Dividend History for Apricus Biosciences (NASDAQ:APRI)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Apricus Biosciences (NASDAQ:APRI)
Insider Ownership Percentage: 3.55%
Institutional Ownership Percentage: 15.27%
Insider Trades by Quarter for Apricus Biosciences (NASDAQ:APRI)
Institutional Ownership by Quarter for Apricus Biosciences (NASDAQ:APRI)
Insider Trades by Quarter for Apricus Biosciences (NASDAQ:APRI)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/31/2017Alexander J DennerMajor ShareholderBuy6,104$1.63$9,949.52View SEC Filing  
3/3/2016Alexander J DennerMajor ShareholderBuy6,647,728$0.88$5,850,000.64View SEC Filing  
1/12/2016Alexander J DennerMajor ShareholderBuy1,306,819$0.88$1,150,000.72View SEC Filing  
12/29/2014Brian DorseyInsiderBuy10,000$1.05$10,500.00View SEC Filing  
12/22/2014Richard W PascoeCEOBuy10,000$1.02$10,200.00View SEC Filing  
10/23/2014Sandford D SmithDirectorBuy26,500$1.57$41,605.00View SEC Filing  
1/3/2014Leonard A OppenheimDirectorSell15,212$2.49$37,877.88View SEC Filing  
12/26/2013Kleanthis G XanthopoulosDirectorSell17,184$2.55$43,819.20View SEC Filing  
6/21/2013Kleanthis G XanthopoulosDirectorSell2,864$2.52$7,217.28View SEC Filing  
5/23/2013Richard W PascoeCEOBuy35,000$2.85$99,750.00View SEC Filing  
5/23/2013Rusty RayDirectorBuy5,000$2.85$14,250.00View SEC Filing  
5/23/2013Steven Robert MartinCFOBuy20,000$2.85$57,000.00View SEC Filing  
5/21/2013Kleanthis G XanthopoulosDirectorSell2,864$3.36$9,623.04View SEC Filing  
8/20/2012Edward M CoxVPBuy1,500$2.73$4,095.00View SEC Filing  
8/17/2012Rusty RayDirectorBuy4,000$2.81$11,240.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Apricus Biosciences (NASDAQ:APRI)
Latest Headlines for Apricus Biosciences (NASDAQ:APRI)
Loading headlines, please wait.



Apricus Biosciences (APRI) Chart for Sunday, October, 22, 2017

This page was last updated on 10/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.